Single-dose gadolinium with magnetization transfer versus tripledose gadolinium in the MR detection of multiple sclerosis lesions

American Journal of Neuroradiology

Volumn 18, Issue 7, 1997, Pages 1279-1285

  Van Waesberghe, J H T M ^a,b   Castelijns, J A ^a   Roser, W ^c   Silver, N ^d   Yousry, T ^e   Lycklama A Nijeholt G J ^a   Ader H J ^b   Uitdehaag, B M J ^a   Radue, E W ^c   Polman, C H ^a   Kappos, L ^c   Miller, D H ^d   Barkhof, F ^a  

^a Dutch MR Centre for MS Research   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Comparative studies; Magnetic resonance; Magnetization transfer; Multiple; Sclerosis

Indexed keywords

GADOLINIUM;

ADULT; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE; SIGNAL PROCESSING;

ADULT; BRAIN; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OBSERVER VARIATION;

EID: 0031545950     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Grossman RI, Gonzalez-Scarano F, Atlas SW. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology 1986;161: 721-725
2. Katz D, Taubenberger JK, Raine CS, McFarlin DE, McFarland H. Gadolinium-enhancing lesions on magnetic resonance imaging: neuropathological findings. Ann Neurol 1990;28:243
3. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991;180:467-474
4. Hawkins CP, Munro PMG, MacKenzie F. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990;113:365-378
5. Hawkins CP, MacKenzie F, Tofts PS, Du-Boulay GH, McDonald WI. Patterns of blood-brain barrier breakdown in inflammatory demyelination. Brain 1991;114:801-810
6. Kermode AG, Tofts PS, Thompson AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990;40:229-235
7. Kermode AG, Thompson AJ, Tofts PS. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain 1990;113:1477-1489
8. Katz D, Taubenberger JK, Cannalla B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-669
9. Miller DH, Rudge P, Johnson G. Serial gadolinium-enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988;11: 927-939
10. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29:548-555
11. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688
12. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62
13. Barkhof F, Scheltens P, Frequin STFM, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 1992;159:1041-1047
14. Thompson AJ, Miller DH, Youl B. Serial gadolinium enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63
15. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766
16. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeglumine-enhancing magnetic resonance imag-ing lesions. Ann Neurol 1993;33:480-489
17. Kidd D, Thompson AJ, Kendall BE, Miller DH, McDonald WI. Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psychiatry 1994;57:1070-1072
18. Khoury SJ, Guttmann CRG, Orav EJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994;44:2120-2124
19. Heun R, Kappos L, Bittkau S, Staedt D, Rohrbach E, Schuknecht B. Magnetic resonance imaging and early diagnosis of multiple sclerosis. Lancet 1988;2:1202-1203
20. Tas MW, Barkhof F, van Walderveen MA, Polman CH, Hommes OR, Valk J. The effect of gadolinium on the sensitivity and specificity of MR imaging in the initial diagnosis of multiple sclerosis. AJNR Am J Neuroradiol 1995;16:259-264
21. Simon JH, Denver CO, Jacobs L, et al. The natural history of MS based on an annual MR snapshot: results from the MSCRG study of intramuscular recombinant interferon beta-1a. Neurology 1995;45(Suppl 4):A418
22. Miller DH. Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol 1994;36(Suppl):S91-S94
23. Barkhof F, Filippi M, Miller DH, Tofts PS, Kappos L, Thompson AJ. Strategies for optimizing MR imaging techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 1997;244:76-84
24. Filippi M, Capra R, Campi A, et al. Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:526-530
25. Filippi M, Yousry T, Rocca MA, Fesl G, Comi G. Sensitivity of delayed enhanced MRI in multiple sclerosis. Proceedings of the International Society for Magnetic Resonance in Medicine. 1996; 1:543
26. Lai M, Hodgson T, McDonald WI, Miller DH. Weekly vs monthly brain MRI for detection of disease activity in multiple sclerosis. J Neurol 1995;242(Suppl 2):S6-S7
27. Guttmann CRG, Ahn SS, Hsu L, Kikinis R, Jolesz FA. The evolution of multiple sclerosis lesions on serial MR. AJNR Am J Neuroradiol 1995;16:1481-1491
28. Thorpe JW, Kidd D, Moseley IF. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996;46:373-378
29. Filippi M, Yousry T, Campi A, et al. Comparison of triple dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996;46:379-384
30. Filippi M, Campi A, Martinelli V, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59:540-544
31. Finelli DA, Hurst GC, Gullapali RP, Bellon EM. Improved contrast of enhancing brain lesions on postgadolinium T1-weighted spin-echo images with use of magnetization transfer. Radiology 1994; 36:62-67
32. Mehta RC, Pike GB, Enzmann DR. Improved detection of enhancing and nonenhancing lesions of multiple sclerosis with magnetization transfer. AJNR Am J Neuroradiol 1995;16:1771-1778
33. Cicchetti DV, Heavens R. A computer program for determining the significance of the difference between pairs of independently derived values for kappa or weighted kappa. Edu Psychol Meas 1981;41:189-193
34. Bozzao A, Bastianello S, Ferone E, Giugni E, Paolillo A, Bozzao L. Enhanced and unenhanced MR with magnetization transfer in multiple sclerosis. AJNR Am J Neuroradiol 1996;17:1837-1842
35. Filippi M, Barkhof F, Bressi S, Yousry T, Miller DH. Interrater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans in patients with multiple sclerosis (MS). J Neurol 1996;243(Suppl 2):S70
36. Tofts PS, Kermode AG. Measurements of the blood-brain barrier permeability and leakage space using dynamic MR imaging, I: fundamental concepts. Magn Reson Med 1991;17:357-367
37. Nauta JJ, Thompson AJ, Barkhof F, Miller DH. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci 1994;22:6-14
38. McDonald WJ, Miller DH, Thompson AJ. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta. Ann Neurol 1994; 36:14-18